Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L5IA
|
|||
| Former ID |
DIB016087
|
|||
| Drug Name |
PEGylated hyaluronidase (human recombinant)
|
|||
| Synonyms |
PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme
Click to Show/Hide
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 1/2 | [1] | |
| Company |
Halozyme Therapeutics San Diego; CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hyaluronidase (HYAL) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02346370) A Phase 1b/2, Study of Pegylated Recombinant Human Hyaluronidase Combined With Docetaxel Versus Docetaxel Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC.. U.S. National Institutes of Health. | |||
| REF 2 | Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.